Why Weight Loss Stalls on GLP-1 Medications (Wegovy or Zepbound)
- kimwohlwend
- 9 hours ago
- 5 min read
Why Am I Not Losing Weight on GLP-1 Medications?
Medications such as Wegovy and Zepbound have helped many people lose weight by reducing appetite, slowing digestion, and improving blood sugar regulation. When combined with lifestyle changes, these medications can lead to meaningful and sustainable weight loss for many patients.
Large clinical trials evaluating GLP-1 medications for weight management have demonstrated significant average weight loss, although individual responses can vary considerably between patients.
However, one of the most common questions people ask is:
“Why has my weight loss stalled even though I’m still taking a GLP-1 medication?”
If you have experienced a weight loss plateau, you are not alone. Weight loss with GLP-1 medications is rarely perfectly linear. Many patients experience periods where the scale slows down or temporarily stops moving before progress resumes again.
Understanding why weight loss stalls on GLP-1 medications can help determine the next steps for continued progress.
Key Takeaways
Weight loss with GLP-1 medications like Wegovy and Zepbound is rarely perfectly linear.
Temporary weight loss plateaus are common and do not necessarily mean the medication has stopped working.
Individual responses to GLP-1 medications vary based on metabolic and clinical factors.
Protein intake, sleep, stress, and medication dosing can influence weight loss progress.
Addressing overall health factors alongside medication therapy may help support continued weight loss.
Quick Answer: Why Weight Loss Stalls on GLP-1 Medications
Weight loss may slow or stall on GLP-1 medications like Wegovy or Zepbound for several common reasons, including:
Natural metabolic adaptation as body weight decreases
Individual variability in metabolic response to treatment
Reduced muscle mass from low protein intake
Medication dosing that has not yet reached an optimal level
Sleep or stress affecting metabolic regulation
Hormonal changes that influence metabolism
Most weight loss plateaus are temporary and can often improve with adjustments to nutrition, activity, sleep, or medication management.
Medical Summary
GLP-1 receptor agonists such as Wegovy and Zepbound mimic the activity of glucagon-like peptide-1, a hormone involved in appetite regulation and glucose metabolism.
These medications help support weight loss by:
Reducing appetite signals in the brain
Slowing gastric emptying
Improving insulin regulation
Increasing feelings of fullness after eating
Clinical studies show that patients using GLP-1 medications for chronic weight management may lose approximately 10–20% of their body weight, although individual outcomes vary depending on metabolic, behavioral, and medical factors.
Because weight regulation is influenced by many physiological systems, weight loss often occurs in phases and temporary plateaus are common.
How Much Weight Do People Typically Lose on GLP-1 Medications?
Clinical trials have shown that patients using GLP-1 medications such as Wegovy and Zepbound may lose approximately 10–20% of their body weight when the medication is combined with lifestyle changes.
However, weight loss typically occurs in phases. Many patients experience periods of steady weight loss followed by temporary plateaus as the body adjusts to changes in metabolism and energy balance.
This pattern is common and does not necessarily mean the medication has stopped working.
Common Reasons Weight Loss Stalls on GLP-1 Medications
1. Metabolic Adaptation and Individual Response
During weight loss, the body naturally adjusts energy expenditure. This process is sometimes referred to as metabolic adaptation, where the body may require fewer calories to maintain a lower weight.
At the same time, responses to GLP-1 medications such as Wegovy and Zepbound can vary significantly between individuals. Research suggests that several factors may influence how much weight a person loses while taking these medications.
Studies have identified trends associated with greater weight loss, including:
Female sex
Younger age
Higher baseline BMI
Lower hemoglobin A1c
Absence of hypertension
These findings highlight that weight loss outcomes with GLP-1 medications are influenced by multiple metabolic and clinical factors, not just medication dose or calorie intake.
Because of this variability, temporary plateaus can occur even when the medication continues to support metabolic changes.
2. Low Protein Intake and Muscle Loss
GLP-1 medications often reduce appetite significantly. While this can help with weight loss, some individuals unintentionally eat too little protein.
Protein plays an important role in preserving lean muscle mass during weight loss. If muscle mass decreases, metabolic rate may decline slightly, which can contribute to slower progress on the scale.
Many patients benefit from focusing on:
Prioritizing protein intake
Maintaining balanced nutrition
Incorporating resistance or strength training
Preserving muscle mass helps support long-term metabolic health and overall body composition.
3. Medication Dose May Need Adjustment
GLP-1 medications are typically started at a lower dose and gradually increased over time to improve tolerability and minimize side effects.
Some patients may experience slower weight loss if they have not yet reached the dose that works best for their body.
A healthcare provider can evaluate progress and determine whether a dose adjustment may be appropriate based on response and tolerance.
4. Sleep and Stress Affect Metabolism
Sleep quality and stress levels can strongly influence metabolism and appetite regulation.
Chronic stress and poor sleep can increase cortisol, a hormone associated with increased abdominal fat storage and changes in appetite regulation.
Improving sleep habits and managing stress may help support overall metabolic health and weight management.
5. Hormonal Changes and Metabolism
Hormonal changes during perimenopause and menopause can influence body composition, metabolism, and fat distribution. Many women notice that weight management becomes more challenging during this time due to shifts in estrogen levels, changes in muscle mass, and alterations in energy balance.
While research continues to explore how hormonal changes interact with GLP-1 medications specifically, these metabolic shifts may still influence overall weight loss patterns in midlife.
For some patients, addressing broader health factors such as hormonal health, sleep quality, and stress levels alongside weight management may help support more sustainable results.
Clinical Perspective
From a clinical standpoint, weight loss plateaus during GLP-1 treatment are common and often reflect normal physiological adaptation rather than treatment failure. In practice, evaluating factors such as nutritional intake, sleep quality, stress levels, hormonal changes, and medication dosing can help determine whether adjustments may support continued progress.
Working with a healthcare provider who understands the interaction between metabolism, hormones, and mental health can help patients take a more comprehensive approach to weight management.
— Kim Wohlwend, MSN, APRN
Medical Weight Loss Care in Papillion and Omaha
Midwest Mind & Body Healthcare provides medically supervised weight loss care for patients in Papillion, Omaha, Bellevue, and surrounding Nebraska communities.
Our clinic takes a comprehensive approach that considers the connection between metabolism, hormones, and mental health. We offer personalized weight loss programs using FDA-approved GLP-1 medications such as Wegovy and Zepbound.
Both in-person visits in Papillion and telehealth appointments are available.
Frequently Asked Questions
Is it normal for weight loss to stall on GLP-1 medications?
Yes. Weight loss plateaus are common with GLP-1 medications. Many patients experience periods where weight loss slows before continuing again.
How long do GLP-1 weight loss plateaus last?
Plateaus may last several weeks. Adjustments to nutrition, activity, sleep, or medication dosing may help support continued progress.
Does a plateau mean the medication stopped working?
Not necessarily. Plateaus are often part of the normal weight loss process as the body adapts to metabolic changes.
Evidence and References
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.Jastreboff AM et al. Tirzepatide once weekly for treatment of obesity. New England Journal of Medicine. 2022.Rubino DM et al. Effect of continued weekly semaglutide vs placebo on weight maintenance. JAMA. 2021.
About the Author
Kim Wohlwend, MSN, APRN is a dual board-certified Family Nurse Practitioner and Psychiatric-Mental Health Nurse Practitioner and founder of Midwest Mind & Body Healthcare in Papillion, Nebraska. Her practice focuses on medical weight loss, hormone health, and mental health care.